Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.47 |
| ▸ | HCN1 | O60741 | 6/20 | 0.46 |
| ▸ | HCN4 | Q9Y3Q4 | 6/20 | 0.45 |
| ▸ | TP53 | P04637 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | THRB | P10828 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2433931 | 0.76 | OPRM1 (0.52) | SIGMAR1OPRM1HCN1HCN4TP53 | |
| SCHEMBL2431727 | 0.75 | PDK1 (0.32) | LMNA | |
| SCHEMBL2433928 | 0.67 | SIGMAR1 (0.48) | SIGMAR1OPRM1HCN1HCN4TP53 | |
| SCHEMBL2428426 | 0.67 | SIGMAR1 (0.46) | SIGMAR1OPRM1HCN1HCN4TP53 | |
| SCHEMBL2427131 | 0.63 | — | — | |
| SCHEMBL4374266 | 0.61 | OPRM1 (0.51) | SIGMAR1OPRM1HCN1HCN4TP53 | |
| SCHEMBL16233192 | 0.60 | TP53 (0.73) | SIGMAR1OPRM1HCN1HCN4TP53 | |
| SCHEMBL2437368 | 0.60 | SIRT1 (0.31) | — | |
| SCHEMBL2435594 | 0.60 | IDO1 (0.35) | LMNA | |
| SCHEMBL16233224 | 0.58 | HCN1 (0.61) | SIGMAR1OPRM1HCN1HCN4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212946-A1 | Quinolone Neuropeptide S Receptor Antagonists | MERCK SHARP & DOHME LLC | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212946-A1 | Quinolone Neuropeptide S Receptor Antagonists | NPSR1, NPY1R, NPY2R | SIGMAR1 194/4885OPRM1 145/4885HCN1 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.